UNASSIGNED: A recent meta-analysis demonstrated that @entity6817 therapy was associated with a risk of @entity6 . The present study investigated whether the relative reduction in low-density lipoprotein @entity165 ( @entity11429 ) was a good indicator of the risk of new-onset @entity6 . We searched the PubMed, Embase, Cochrane Central Register, Lilacs, Food and Drug Administration, and European Medicines Agency databases for randomized controlled trials of statins. Fourteen trials were included in the study. Eight trials with target @entity11429 levels <= 100   mg/dL (2.6   mmol/L) or @entity11429 reductions of at least 30% were extracted separately. The results showed that the overall risk of incident @entity6 increased by 11% (OR   =   1.11; 95% CI 1.03-1.20). The group with intensive @entity11429 -lowering statin had an 18% increase in the likelihood of developing @entity6 (OR   =   1.18; 95% CI, 1.10-1.28). Furthermore, the risks of incident @entity6 were 13% (OR   =   1.13; 95% CI 1.01-1.26) and 29% (OR   =   1.29; 95% CI 1.13-1.47) in the subgroups with 30-40% and 40-50% reductions in @entity11429 , respectively, suggesting that @entity11429 reduction may provide a dynamic risk assessment parameter for new-onset @entity6 . In conclusion, @entity11429 reduction is positively related to the risk of new-onset @entity6 . When @entity11429 is reduced by more than 30% during lipid-lowering therapy, blood @entity413 monitoring is suggested to detect incident @entity6 in high-risk populations.

Association between reductions in low-density lipoprotein XXXX with statin therapy and the risk of new-onset @entity6 : a meta-analysis.

@entity6 :: ('MESH:D003920', 'Disease') :: ['diabetes'] @entity6817 :: ('D019821', 'Chemical') :: ['statin'] @entity11429 :: ('22796', 'Gene') :: ['LDL-c'] @entity413 :: ('MESH:D005947', 'Chemical') :: ['glucose'] @entity165 :: ('MESH:D002784', 'Chemical') :: ['cholesterol']
@entity165 :: (MESH:D002784,Chemical) :: ['cholesterol']
